Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 8

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 8
---
 
  
    Net Proceeds from January 2025 Offering 
     804,346  
     - 
  
    Net Proceeds from February 2025 Offering 
     908,627  
     - 
  
    Shares Withheld for Net Share Settlement of Performance Bonuses 
     (18,000) 
     - 
  
    Proceeds from Exercise of Pre-Funded Warrants 
     1,926  
     4,995 
  
    Net Cash Provided by Financing Activities 
     1,696,899  
     1,903,291 

    Effect of Exchange Rate Changes on Cash 
     (9,904) 
     (824)

    Change in Cash and Cash Equivalents 
     1,792,147  
     752,215 
  
    Cash and Cash Equivalents—Beginning of Period 
     1,659,353  
     2,142,485 
  
    Cash and Cash Equivalents—End of Period 
    $3,451,500  
    $2,894,700 

    NONCASH INVESTING/FINANCING ACTIVITIES 

    Fair Value of Warrants Issued to Underwriters 
    $-  
    $71,364 
  
    Purchases of Fixed Assets included in Accounts Payable 
    $10,000  
    $- 
  
    Gross Shares Issued for Annual Performance Bonuses 
    $121,544  
    $- 

The accompanying notes are an integral part
of these unaudited consolidated condensed financial statements.

5

60 DEGREES PHARMACEUTICALS, INC.

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS

1. NATURE OF OPERATIONS

60 Degrees Pharmaceuticals, Inc. was incorporated
in Delaware on June 1, 2022 and merged on the same day with 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability
company organized on September 9, 2010 (“60P LLC”). 60 Degrees Pharmaceuticals, Inc. and its subsidiary (referred to collectively
as the “Company”, “60P”, or “60 Degrees Pharmaceuticals”) is a specialty pharmaceutical company that
specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. 60P achieved FDA
approval of its lead product, ARAKODA®